Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer

Int J Mol Sci. 2023 May 12;24(10):8642. doi: 10.3390/ijms24108642.

Abstract

Various lung diseases endanger people's health. Side effects and pharmaceutical resistance complicate the treatment of acute lung injury, pulmonary fibrosis, and lung cancer, necessitating the development of novel treatments. Antimicrobial peptides (AMPs) are considered to serve as a viable alternative to conventional antibiotics. These peptides exhibit a broad antibacterial activity spectrum as well as immunomodulatory properties. Previous studies have shown that therapeutic peptides including AMPs had remarkable impacts on animal and cell models of acute lung injury, pulmonary fibrosis, and lung cancer. The purpose of this paper is to outline the potential curative effects and mechanisms of peptides in the three types of lung diseases mentioned above, which may be used as a therapeutic strategy in the future.

Keywords: antimicrobial peptide; fibrosis; infection; lung cancer; lung disease; therapeutic peptides.

Publication types

  • Review

MeSH terms

  • Acute Lung Injury* / drug therapy
  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Cationic Peptides / chemistry
  • Antimicrobial Cationic Peptides / pharmacology
  • Antimicrobial Cationic Peptides / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Pulmonary Fibrosis* / drug therapy

Substances

  • Antimicrobial Cationic Peptides
  • Anti-Bacterial Agents